UK Clinical Trial Confirms SaNOtize’s Breakthrough Treatment for COVID-19
Patients with a self-administered nasal spray application found to have reduced SARS-CoV-2 log viral load by more than 95% in infected participants within 24 hours of treatment, and by more than 99% in 72 hoursTrial concluded that treatment accelerated clearance of SARS-CoV-2 by a factor of 16-fold versus a placebo Randomized, double-blind, placebo-controlled trial evaluated 79 confirmed cases of COVID-19, the majority heavily-infected with the UK variant No adverse events were recorded in the group Submission for Emergency Use in the UK and Canada for the treatment and prevention of COVID-19 is planned immediately VANCOUVER, British Columbia & SURREY, England--(BUSINESS WIRE)--Biotech company SaNOtize Research & Development Corp., (SaNOtize), Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey, UK, and Berkshire and Surrey Pathology Services, UK, today announced results of clinical trials indicating that SaNOtize’s Nitric Oxide Nasal Spray (NONS) represents a safe ...
Comments
Post a Comment